Hikma Pharmaceuticals (HKMPY)
OTC: HKMPY
· Real-Time Price · USD
49.25
-0.15 (-0.30%)
At close: Oct 03, 2025, 12:19 PM
Hikma Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
Fiscal Year | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 |
Period Ending | Jun 30, 2025 | Dec 31, 2024 | Jun 30, 2024 | Dec 31, 2023 | Jun 30, 2023 | Dec 31, 2022 | Jun 30, 2022 | Dec 31, 2021 | Jun 30, 2021 |
Revenue | 3.22B | 3.13B | 3.01B | 2.86B | 2.79B | 2.58B | 2.56B | 2.57B | 2.4B |
Cost of Revenue | 1.83B | 1.71B | 1.63B | 1.55B | 1.48B | 1.38B | 1.35B | 1.35B | 1.25B |
Gross Profit | 1.33B | 1.37B | 1.38B | 1.31B | 1.31B | 1.2B | 1.21B | 1.22B | 1.15B |
Operating Income | 493.61M | 585.61M | 476M | 473M | 611.29M | 518.29M | 558.8M | 599.8M | 559.2M |
Interest Income | 7.99M | 7.96M | 7.97M | 6.97M | 5.1M | 3.1M | 19M | 19M | 4.93M |
Pretax Income | 462M | 455M | 366.37M | 280.37M | 220.88M | 233.88M | 441.08M | 545.08M | 597.91M |
Net Income | 369.66M | 357.66M | 284.53M | 189.53M | 146.73M | 188.73M | 347.61M | 422.61M | 463.08M |
Selling & General & Admin | 573.99M | 575.99M | 694.68M | 674.68M | 540.07M | 536.07M | 498.23M | 474.23M | 461.81M |
Research & Development | 152.19M | 140.19M | 145.32M | 148.32M | 142.67M | 147.67M | 153.78M | 143.78M | 132.66M |
Other Expenses | 137.81M | 86.81M | 63.01M | -18.99M | -18M | n/a | n/a | n/a | n/a |
Operating Expenses | 864M | 803M | 903.01M | 840.01M | 700.74M | 683.74M | 652.01M | 618.01M | 594.46M |
Interest Expense | 83.9M | 87.56M | 86.66M | 86.66M | 90.15M | 79.15M | 64.29M | 56.29M | 54.46M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 2.7B | 2.52B | 2.53B | 2.39B | 2.18B | 2.06B | 2B | 1.97B | 1.84B |
Income Tax Expense | 88.66M | 92.66M | 76.86M | 88.86M | 72.05M | 42.05M | 94.49M | 124.49M | 135.82M |
Shares Outstanding (Basic) | 111.21M | 110.32M | 111.88M | 111.37M | 111.02M | 110.23M | 113.97M | 116.98M | 116M |
Shares Outstanding (Diluted) | 111.21M | 111.52M | 111.88M | 111.37M | 111.02M | 110.91M | 114M | 117M | 116M |
EPS (Basic) | 3.36 | 3.24 | 2.58 | 1.72 | 1.32 | 1.66 | 3.00 | 3.62 | 4.02 |
EPS (Diluted) | 3.32 | 3.20 | 2.54 | 1.70 | 1.32 | 1.66 | 3.00 | 3.62 | 4.02 |
EBITDA | 784.86M | 735.86M | 641.28M | 660.28M | 730M | 625M | 688.2M | 769.2M | 800.1M |
EBIT | 582.88M | 539.88M | 451.04M | 429.04M | 374.04M | 313.04M | 505.37M | 601.37M | 652.38M |
Depreciation & Amortization | 201.98M | 195.98M | 190.25M | 190.25M | 197.75M | 194.75M | 182.83M | 167.83M | 147.73M |